CTIS2023-504567-17-00
Recruiting
Phase 1
Safety and efficacy of botulinum toxin A in patients with trigeminal neuralgia: a double-blind, randomized, placebo-controlled, parallel-group trial and investigation of neuro-inflammatory biomarkers as predictors of efficacy
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Trigeminal neuralgia
- Sponsor
- Rigshospitalet
- Enrollment
- 80
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A diagnosis of classical trigeminal neuralgia or idiopathic trigeminal neuralgia according to criteria of The International Classification of Headache Disorders 3rd edition., Age between 18 and 85 years, Subjects must experience pain defined as minimum one TN related pain paroxysm per day of an average intensity of 3 to 10, inclusive, on the 11\-point NRS (0 \= no pain; 10 \= maximum pain imaginable) during the last 4 weeks to enter the baseline phase., During baseline phase subjects must experience pain defined as minimum one TN related pain paroxysm per day of an average intensity of 3 to 10, inclusive, on the 11\-point NRS (0\= no pain; 10\= maximum pain imaginable) to be randomized., Fluency in Danish
Exclusion Criteria
- •Severe cardiovascular and cerebrovascular disease such as ischemic heart disease, myocardial infarction or previous stroke or transient ischemic attack, major CVD interventions during the last three months., Expected poor compliance, i.e., considered unlikely to be able to complete all protocol required study visits or procedures, and/or to comply with all required study procedures to the best of the subject’s and investigator’s knowledge, Ongoing and unstable severe psychiatric disease., Anamnestic or clinical symptoms of any kind that are deemed relevant for study participation by the physician who examines the patient., Change of trigeminal neuralgia treatment or treatment dose within two weeks prior to the baseline visit., Previous treatment with botulinum toxin A for facial pain., Loading treatment within 4 weeks with phenytoin or sodium valproate., Female subjects either pregnant, breastfeeding or with planned conception within the study period., Female subject of childbearing potential who is unwilling to use an acceptable method of effective contraception during the study (see protocol for acceptable methods).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Botulinum toxin type A for plantar hyperhidrosisplantar hyperhidrosisJPRN-jRCTs041210062Ohshima Yuichiro40
Active, not recruiting
Phase 4
To check wrinkle free forehead after injection of Botulinum drug.CTRI/2015/03/005613Dr L Krishna Prasad Head of department Department of oral and maxillofacial surgery
Completed
Not Applicable
The efficacy and safety of botulinum toxin type B on digital ulcers in patients with systemic sclerosisdigital ulcers in systemic sclerosis patientsJPRN-UMIN000024818Gunma University Hospital10
Not yet recruiting
Phase 2
Onabotulinum toxin A (Botox) in the treatment of central nervous system dysfunction related swallowing difficultyCTRI/2021/01/030809AIIMS
Completed
Not Applicable
Study of safety and duration of action of single dose (7.5 units) of botulinum toxin injection in patients with functional epiphora and proximal lacrimal drainage blockHealth Condition 1: H042- EpiphoraCTRI/2021/03/031793Dept of Ophthalmology Command Hospital Kolkata31